Olaparib Dosage

Usual Adult Dose for Ovarian Cancer

Initial dose: 400 mg (eight 50 mg capsules) orally twice a day
Duration of therapy: Continue treatment until disease progression or unacceptable toxicity

Comments: Patients should be selected based on the presence of deleterious or suspected deleterious germline BRCA-mutations, as detected by an approved test.

Use: Monotherapy in patients with deleterious or suspected deleterious germline BRCA mutated advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy

Renal Dose Adjustments

-Mild Renal Dysfunction (CrCl 50 to 80 mL/min): No adjustment required, but close monitoring for toxicity recommended
-Moderate and Severe Renal Dysfunction (CrCl less than 50 mL/min): Data not available

Liver Dose Adjustments

Data not available

Dose Adjustments

To manage adverse reactions, consider treatment interruption or dose reduction:
-1st dose reduction: 200 mg (four 50 mg capsules) orally twice a day
-2nd final dose reduction: 100 mg (two 50 mg capsules) orally twice a day

Avoid concomitant use of CYP450 3A inhibitors and consider alternative agents. If concomitant use cannot be avoided:
-Reduce dose to 200 mg (four 50 mg capsules) orally twice a day when used with moderate CYP450 3A inhibitor
-Reduce dose to 150 mg (three 50 mg capsules) orally twice a day when used with strong CYP450 3A inhibitor

Precautions

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:
-In the event of a missed dose, advise patients to take their next dose at its scheduled time. Patients should not take an extra dose to make up for the missed dose.
-Advise patients to avoid grapefruit, grapefruit juice, and Seville oranges during treatment as they may increase the level of this drug in the blood.
-Capsules should be swallowed whole; do not chew, dissolve, or open.
-Capsules which appear deformed or show evidence of leakage should not be taken.

Monitoring:
-Monitor complete blood count testing at baseline and monthly thereafter.
-For prolonged hematological toxicities, monitor blood counts weekly and interrupt treatment until recovery.